Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816625 | 0.93 | TRPV1 (0.38) | TRPV1NTRK1GLSNAMPTBCDIN3D | |
| SCHEMBL3811826 | 0.93 | KMT2A (0.39) | KMT2AMAPK11MAPK14NPC1MAPT | |
| SCHEMBL3812466 | 0.90 | DGAT2 (0.39) | TRPV1NTRK1GLSBCDIN3DDGAT2 | |
| SCHEMBL3820599 | 0.87 | KMT2A (0.39) | KMT2AMAPK11MAPK14NPC1MAPT | |
| SCHEMBL3821871 | 0.86 | GLS (0.39) | KMT2AMAPK11MAPK14NPC1MAPT | |
| SCHEMBL3816617 | 0.85 | SMN1; SMN2 (0.48) | KMT2AMAPK14NPC1MAPTPKM | |
| SCHEMBL3821662 | 0.85 | KMT2A (0.58) | KMT2AMAPTSMN1; SMN2NAMPT | |
| SCHEMBL14388159 | 0.84 | KMT2A (0.40) | KMT2AMAPK11MAPK14NPC1PKM | |
| SCHEMBL3813353 | 0.83 | MAPT (0.45) | KMT2ANPC1MAPTPKMRAB9A | |
| SCHEMBL5822872 | 0.82 | CNR2 (0.41) | KLKB1GLSNAMPTPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-2089018-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008067121-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | KMT2A 651/4885MAPK11 1915/4885MAPK14 3333/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | KMT2A 464/4885MAPK11 3024/4885MAPK14 4283/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | KMT2A 426/4885MAPK11 2515/4885MAPK14 4156/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | KMT2A 4307/4885MAPK11 3348/4885MAPK14 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.